Terminated PHASE3 INTERVENTIONAL 2-arm NCT02629848

Study of Motesanib (AMG 706) in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer

A Global Phase 3, Randomized, Placebo Controlled, Double-Blind Trial of AMG 706 in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer (Asian Phase 3 Study)

Sponsor: Takeda

Conditions Carcinoma, Non-Small-Cell Lung

Interventions Carboplatin Motesanib Paclitaxel Placebo

Updated 4 times since 2017 Last updated: Dec 10, 2015 Started: Jul 31, 2012 Primary completion: Sep 30, 2014 Completion: Mar 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor decision to terminate the study because the study did not meet the primary endpoint.

Other terminated trials from Takeda

See all terminations from Takeda

Other Carcinoma, Non-Small-Cell Lung trials with similar outcome

Browse all Carcinoma, Non-Small-Cell Lung trials

This PHASE3 trial investigates Carcinoma, Non-Small-Cell Lung and is currently terminated or withdrawn. Takeda leads this study, which shows 4 recorded versions since 2012 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE3
Jan 2017 — Jan 2021 [monthly]

Terminated PHASE3

First recorded

Jul 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Takeda

Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.